HAZLET, N.J. - s4story -- To address the needs of HF clinicians, this educational initiative will provide case-based learning (after brief summaries of clinical evidence) and commentary by leading HF experts on implications of use of SGLT2 inhibitors in everyday clinical practice.

Click here for more information

CHAIR

Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts

FACULTY

Stephen Greene, MD
Assistant Professor
Division of Cardiology
Duke University Medical Center/Duke Clinical Research Institute
Durham, North Carolina

Mikhail Kosiborod, MD
Vice President of Research
Saint Luke's Health System
Professor of Medicine
University of Missouri-Kansas City
Kansas City, Missour

Alanna Morris, MD, MSc

More on S For Story

• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)

Associate Professor of Medicine
Director of Heart Failure Research
Emory University Clinical Cardiovascular Research Institute
Atlanta, Georgia

This educational activity is intended for clinicians treating patients with heart failure.

Voxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Voxmedia LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.25 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-L04-P.

Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #HFSA2023 #SGLT2 #heartfailure